BioSpace News Archive

Labcorp, a leading global life sciences company, announced the opening of a new diagnostics laboratory in South Bend, Indiana, allowing the company to enhance service levels and offerings to patients and physicians in South Bend and throughout the region.

Ascletis Pharma Inc. announces the positive in vivo and in vitro data of oral double prodrug ASC10 and its antiviral nucleoside analog ASC10-A against multiple SARS-CoV-2 virus variants including Omicron.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Elizabeth “Bess” Weatherman has been appointed to the Company’s Board of Directors.

OneOncology, the national platform for independent community oncology practices, announced that Davey Daniel, MD has been appointed Chief Medical Officer succeeding Lee Schwartzberg, MD.

Cullinan Oncology, Inc. announced that it will be participating in SVB Leerink’s 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.

Eliem Therapeutics, Inc. announced it will host a virtual investor event, featuring two opinion leaders in chronic pain, that will be held on Wednesday, February 16, 2022 starting at 10:30 a.m. ET.

Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 vaccine.

Evelo Biosciences, Inc. today announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis.

CareDx, Inc. is hosting a webinar focused on educating kidney transplant on how to maintain optimal heart health to help prevent cardiovascular complications, which can contribute to kidney transplant failure.

uniQure N.V. today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.